返回 
加入收藏
利拉鲁肽致胰腺炎的文献病例分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 利拉鲁肽致胰腺炎的文献病例分析 |
| TITLE： | Literature case analysis of liraglutide-induced pancreatitis |
| 摘要： | 目的 分析利拉鲁肽致胰腺炎的临床特点，为临床合理用药提供参考。方法计算机检索中国知网、维普网、万方数据、PubMed、WebofScience和Medline数据库，收集利拉鲁肽致胰腺炎的个案报道，检索时限为从建库起至2022年12月31日，描述性分析患者人口学特征、用药情况、临床表现、干预与转归等。结果共纳入文献17篇，涉及17例患者，其中男性7例、女性10例，年龄为25～75岁；均有用药指征，包括2型糖尿病14例，肥胖或超重3例；其中单一用药5例，合并用药12例。17例患者胰腺炎的发生时间均为利拉鲁肽用药后1d～11个月，大多出现在6个月以内（14例）；主要临床表现包括腹痛、恶心和呕吐等。诊断为胰腺炎后，16例停用利拉鲁肽，其中1例未予其他干预，15例予以对症治疗，16例患者症状均缓解，但2例在利拉鲁肽停用数周后再次发生胰腺炎，且均为重度胰腺炎，1例患者再次应用利拉鲁肽后胰腺炎再次发生。关联性评价结果显示，1例为“肯定”，4例为“可能”，其余患者为“很可能”。结论利拉鲁肽致胰腺炎多发生在用药6个月内，多为轻度、中重度，但也可能出现严重甚至致命的病例。临床在应用利拉鲁肽时，应定期监测患者胰酶水平并密切观察其临床表现，若出现疑似利拉鲁肽诱发的胰腺炎，应尽早停药并给予对症治疗。 |
| ABSTRACT： | OBJECTIVE To analyze the clinical characteristics of liraglutide-induced pancreatitis， and to provide reference for clinical rational drug use. METHODS Retrieved from CNKI， VIP， Wanfang database， PubMed， Web of Science and Medline， case reports about liraglutide-induced pancreatitis were collected from the inception to December 31st， 2022. Demographic characteristics， drug use， clinical manifestations， intervention and outcome were analyzed using descriptive statistical method. RESULTS A total of 17 pieces of literature were collected and 17 patients were involved， including 7 males and 10 females. The patients aged from 25 to 75 years. All 17 patients had drug indications， including 14 cases of type 2 diabetes mellitus， 3 cases of obesity or overweight. Among 17 patients， liraglutide was used alone in 5 cases， and combined with other drugs in 12 cases. Time from liraglutide administration to pancreatitis occurrence ranged from 1 day to 11 months after medication in 17 patients， with 14 cases less than 6 months. The clinical manifestations mainly included abdominal pain， nausea and vomiting， etc. After the diagnosis of pancreatitis， liraglutide discontinuation occurred in 16 patients； 1 case did not receive any other interventions and the other 15 cases were managed with symptomatic supportive treatment； the symptoms of all 16 patients resolved； however， 2 patients suffered from second episode of severe pancreatitis several weeks after liraglutide discontinuation， pancreatitis recurred after liraglutide rechallenge in 1 case. The results of correlation evaluation showed that 1 case was “positive”， 4 cases were “possible”， and the remaining patients were “very likely”. CONCLUSIONS Liraglutide-induced pancreatitis mainly occurred within 6 months after drug administration. The majority of liraglutide-induced pancreatitis cases are mild to moderate， but there are also severe and even fatal cases. It is advisable to periodically monitor the level of pancreatic enzymes and closely observe patients’ clinical mani-festations. In case of suspected liraglutide-induced pancreatitis，drug withdrawal and symptomatic treatment should be taken immediately. |
| 期刊： | 2023年第34卷第12期 |
| 作者： | 卢翠翠；弭玮；李霞；张旭升；沈承武 |
| AUTHORS： | LU Cuicui，MI Wei，LI Xia，ZHANG Xusheng，SHEN Chengwu |
| 关键字： | 利拉鲁肽；胰腺炎；2型糖尿病；胰高血糖素样肽-1受体激动剂；文献病例分析 |
| KEYWORDS： | liraglutide； pancreatitis； type 2 diabetes |
| 阅读数： | 182 次 |
| 本月下载数： | 8 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
